Localization of Neuroendocrine Tumors Using Somatostatin Receptor Imaging With Indium-111-Pentetreotide (OctreoScan)

Area of Science:

• Nuclear Medicine
• Oncology
• Gastroenterology

Background:

• Conventional imaging techniques struggle to detect small gastrointestinal neuroendocrine tumors (<1.0 cm).
• A definitive gold standard for locating primary tumors and metastases is lacking.
• Neuroendocrine tumors (NETs) present diagnostic challenges due to their varied locations and potential for metastasis.

Purpose of the Study:

• To evaluate the efficacy of 111-In-pentetreotide scintigraphy for imaging abdominal neuroendocrine tumors.
• To compare the detection rates of 111-In-pentetreotide with conventional imaging methods.
• To assess the safety and effectiveness of 111-In-pentetreotide in a large patient cohort.

Main Methods:

• A nine-center European study involving 365 patients with gastroenteropancreatic neuroendocrine tumors.
• Utilized 111-In-pentetreotide as a radiotracer for scintigraphy.
• Compared scintigraphy results with other conventional imaging modalities.

Main Results:

• 111-In-pentetreotide demonstrated agreement with conventional methods in 79% of tumor locations.
• Detected 110 additional tumor localizations not identified by conventional techniques.
• Successfully imaged a 4-mm duodenal gastrinoma, highlighting sensitivity for small tumors. The agent is cleared rapidly by the kidneys with a six-hour half-life, with spleen and kidneys receiving the highest radiation dose.

Conclusions:

• Scintigraphy with 111-In-pentetreotide is effective for visualizing somatostatin receptors on gastrointestinal neuroendocrine tumors.
• Insulinomas are not optimally imaged with this agent.
• Concurrent computed tomography (CT) scanning is advised to improve the detection of liver metastases and minimize missed diagnoses.